Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis

Interferon beta (IFNβ) is the most common immunomodulatory treatment for relapsing-remitting multiple sclerosis (RRMS). However, some patients fail to respond to treatment. In this study, we identified putative clinical response markers in the serum and plasma of people with multiple sclerosis (MS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Kaushal S., McKay, Fiona C., Diefenbach, Eve, Crossett, Ben, Schibeci, Stephen D., Heard, Robert N., Stewart, Graeme J., Booth, David R., Arthur, Jonathan W.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864746/
https://www.ncbi.nlm.nih.gov/pubmed/20463963
http://dx.doi.org/10.1371/journal.pone.0010484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864746/
https://www.ncbi.nlm.nih.gov/pubmed/20463963
http://dx.doi.org/10.1371/journal.pone.0010484

Ejemplares similares